ASX RELEASE

13 JANUARY 2026

TETRATHERIX HITS MAJOR CLINICAL MILESTONE: TETRADERM CLINICAL TRIAL ADVANCES TO THIRD AND FINAL COHORT

HIGHLIGHTS:

- Tetratherix is pleased to announce the **successful completion of the second safety review** meeting of the second cohort of the TetraDerm clinical trial that is studying the product's ability to **prevent scar formation** in surgical incisions.
- 9 patients in the second cohort of the TetraDerm clinical trial have successfully completed their **6 week follow up assessments**.
- No procedural or technical adverse events have been observed or reported which **confirms the differentiated and market leading safety profile of the product**.
- Based on the clinical observations from the first and second cohorts of patients, the principal investigator, Dr Drew Cronin will begin patient enrolment for the **third cohort in the first quarter of CY2026**.
- The majority of the third cohort will be represented by the fast-growing segment of the plastic and reconstructive surgical market that includes patients undergoing body contouring procedures resulting from weight loss following the recent rapid uptake of obesity and weight loss treatments.
- Patient recruitment in the **third cohort of the TetraDerm clinical trial has been initiated,** the final validation stage of TetraDerm's pre-commercialisation pathway.

Tetratherix Limited (ASX:TTX) (Tetratherix), a developer of novel clinical products based on its patented biomaterial polymer platform technology, is pleased to announce the successful completion of the second safety review meeting of the second cohort of the TetraDerm clinical trial. The successful completion of the second safety review of the second cohort of the TetraDerm clinical trial with zero procedural or technical adverse events further confirms that Tetratherix's patented biomaterial platform integrates seamlessly with human tissue.

Dr Drew Cronin, principal investigator of the TetraDerm clinical trial, said:

"As we mark the completion of a significant milestone in our clinical trial, I am excited to treat patients with TetraDerm post-major surgeries that involve incision sites of up to 1.5 meters in length. This advancement has been only possible by the execution of a **meticulous development program,** implemented to test TetraDerm in preclinical models and this staged clinical evaluation. This enables us to transition from addressing wounds in the face and neck to tackling major surgical sites, which holds the potential to **significantly enhance the quality of life of our patients**."

SEE OVER

While patient safety remains the fundamental baseline for surgical success, the transition of the TetraDerm clinical trial into the third cohort is pivotal to illustrate TetraDerm's ability to address the profound psychological and physical toll of scarring. For patients undergoing surgical procedures, surgical scars often serve as sources of post-surgical trauma frequently accompanied by physical complications like neuropathic pain and restricted mobility or the need for costly revisionary surgeries.

The safety profile proven in the second cohort of the TetraDerm clinical trial may prove to be highly disruptive for surgical site management. It provides the necessary safety foundation for TetraDerm to **reduce wound tension and optimise the healing environment** ultimately offering a more aesthetic, reliable solution for the complex and large-scale surgeries required in, amongst others, the rapidly growing reconstructive surgical market resulting from weight loss following the recent rapid uptake of obesity and weight loss treatments. While millions are achieving dramatic weight loss, approximately 60% of GLP-1 patients who lose 11%–30% of their body weight eventually seek aesthetic treatments to address the resulting excess skin.

As the obesity and weight loss medication market continues to expand rapidly, the resulting demand for clinical proven safe and effective body contouring products like TetraDerm is expected to grow exponentially. By targeting patients in the third cohort of the TetraDerm clinical study who have achieved significant weight loss, Tetratherix is entering a high-volume market with a clear, unmet need for advanced reconstructive surgical materials.

Will Knox, CEO of Tetratherix, said:

"The further technical validation of our TetraDerm product is extremely promising. Clearing our second safety review with zero adverse events confirms our platform **performs exactly as engineered in high-stakes clinical settings**. I want to thank Dr Drew Cronin for his expert leadership in steering these first two cohorts to this milestone. As we move into the third cohort we are positioned at the epicentre of surgical site management. We aren't just filling a clinical gap; we are delivering a high-margin, scalable solution to a multi-billion-dollar problem."

< ENDS >

Authorised for ASX release by the CEO.

For further information, please contact:

Jacob Pfeffer
General Counsel and Company Secretary
+61 425 194 200
jacob.pfeffer@tetratherix.com
https://tetratherix.com/